Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institute on Aging (NIA) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) National Center on Minority Health and Health Disparities (NCMHD) Office of Research on Women's Health (ORWH) |
---|---|
Information provided by: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
ClinicalTrials.gov Identifier: | NCT00004992 |
The Diabetes Prevention Program is a nationwide clinical study to answer the question: Can Type 2 diabetes (also called noninsulin-dependent or adult-onset diabetes) be prevented or delayed? The study has recruited 3819 volunteers, who are at high risk of developing diabetes, at twenty-five medical centers in the United States. It is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, and other Institute and corporate sponsors. Researchers will evaluate the efficacy of a lifestyle intervention and a pharmacological intervention in preventing or delaying Type 2 diabetes in persons with IGT, impaired glucose tolerance. Each person in the study will be followed for 3 to 6 years.
Condition | Intervention |
---|---|
Diabetes Mellitus, Non-Insulin-Dependent Glucose Intolerance |
Behavioral: Intensive lifestyle |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Placebo Control |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Maryland | |
George Washington University Biostatistics Center, Suite 750, 6110 Executive Blvd | |
Rockville, Maryland, United States, 20852 |
Principal Investigator: | Sarah Fowler, PhD |
Study ID Numbers: | DPP, DK48489 |
Study First Received: | March 17, 2000 |
Last Updated: | November 27, 2006 |
ClinicalTrials.gov Identifier: | NCT00004992 |
Health Authority: | United States: Food and Drug Administration |
clinical trial multi-center NIDDM NIDDK DPP diabetes risk factors diabetes glycemia cardiovascular risk factors |
quality of life physical activity and nutrition occurrence of adverse events insulin secretion and sensitivity prevention abnormal glucose metabolism lifestyle intervention drug intervention |
Hyperglycemia Metabolic Diseases Diabetes Mellitus, Type 2 Glucose Intolerance Diabetes Mellitus Quality of Life |
Endocrine System Diseases Endocrinopathy Metabolic disorder Glucose Metabolism Disorders Insulin |